CDC advisers recommend spring Covid boosters for older adults

CDC advisers recommend spring Covid boosters for older adults


A pharmacist delivers a COVID-19 booster dose at a Chicago CVS store.

Antonio Perez | Tribune News Service | Getty Images

People at higher risk for the most severe complications of Covid — primarily those ages 65 and older — should receive a booster shot this spring, advisers to the Centers for Disease Control and Prevention said Wednesday.

Another round of the vaccine given within the next few months would offer the best protection possible, they said, ahead of another likely rise in illness this summer.

Over the past four years, there’s tended to be both a winter and a summer wave of Covid, with cases peaking in January and August, respectively, according to the CDC.

For that reason, advisers to the CDC said that the approach to Covid vaccination is still different from the strategy used for the flu, which typically only peaks during the winter.

“I hope that we are moving in the direction of getting more flu-like where there’s a really clear season, but I don’t think that we are there yet,” Megan Wallace, a CDC epidemiologist, said during Wednesday’s meeting of the agency’s Advisory Committee on Immunization Practices.

The panel’s vote to recommend spring boosters for older adults is not final until CDC Director Dr. Mandy Cohen signs off on it. She does not have to follow the committee’s advice, but usually does. An official CDC recommendation is needed for health insurance providers to cover the additional dose.

The additional dose should be given at least four months after a previous dose for healthy older adults, or at least three months after a Covid infection. People with compromised immune systems may need additional shots.

“This gives us a great opportunity to remind people about the importance of vaccination,” said Marvia Jones, director of the Kansas City Health Department in Missouri, who was not involved in Wednesday’s ACIP meeting. “We certainly are concerned about the vulnerability of people in that age group when it comes to Covid-19.”

The spring booster would be the same shot that was approved last fall, which was formulated to target the XBB.1.5 subvariant. The vaccine is effective against the JN.1 subvariant, which is currently causing the vast majority — more than 96% — of new Covid infections in the United States.

On Wednesday, the advisory committee presented new data showing that the shot lowered the odds of being hospitalized with Covid in otherwise healthy people 65 years and older by up to 54%.

The CDC will publish additional details on that research Thursday.

Covid hospitalizations peaked at the beginning of January, with 35,000 hospitalizations a week. By Feb. 7, Covid hospitalizations had fallen to around 20,000 a week.

Throughout the last year, weekly hospital admissions for Covid never dipped below 6,000, the CDC said. The vast majority have been among older adults, 65 and older.

The number of Covid deaths are also decreasing. Still, at the lowest point last summer, the CDC reported about 500 Covid deaths a week.

A resident receives a Covid-19 booster shots at a vaccine clinic inside Trinity Evangelic Lutheran Church in Lansdale, Pennsylvania, U.S, on Tuesday, Apr. 5, 2022.

Hannah Beier | Bloomberg | Getty Images



Source

CDC takes down more than a dozen webpages on sexual and gender identity, health equity
Health

CDC takes down more than a dozen webpages on sexual and gender identity, health equity

A sign for the CDC sits outside of their facility at the Centers for Disease Control and Prevention Roybal campus in Atlanta, Georgia, U.S., May 30, 2025. Megan Varner | Reuters More than a dozen pages on the Centers for Disease Control and Prevention website related to sexual and gender identity, health equity, and other […]

Read More
We’re buying the dip in a health and life sciences stock that has gone down enough
Health

We’re buying the dip in a health and life sciences stock that has gone down enough

We’re buying 20 more shares of Danaher at roughly $180 each. Following Thursday’s trade, Jim Cramer’s Charitable Trust will own 470 shares of DHR, increasing its weighting to about 2.31% from about 2.22%. While Danaher has certainly been one of a handful of problematic stocks in the portfolio, we are stepping into the name here, […]

Read More
Roche targets becoming top 3 obesity player as experimental drug enters late-stage trial
Health

Roche targets becoming top 3 obesity player as experimental drug enters late-stage trial

The Roche Holding AG headquarters on April 11, 2025, in Basel, Switzerland. Sedat Suna | Getty Images News | Getty Images Swiss pharmaceutical firm Roche is targeting becoming a top three obesity player globally, posing a potential rival to heavyweights Novo Nordisk and Eli Lilly as it advances one of its experimental weight-loss drugs to […]

Read More